Vascular Biogenics Ltd (VBLT)

[Oren1976]

. "So I can tell you that the percentage of patients developing fever is actually similar to what we've seen in all our Phase 2 trials, is about 40% so far. I can tell you that in the blinded data, the one developing fever, doing quite well in their C-125 response. So there are a lot of signals that we have a good chance to repeat what we've seen in the Phase 2"

Am I get it right ? Did they ceo just said we know that in the phase 3 40% reacted with fever and we also know these 40% had reduction in ca125 ? If yes then he just revealed a readout of 80% of interim because he said 20% missing from 60 patients before that